MedGemma vs Wysa vs Airdoc 鹰瞳科技 vs Lunit
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
MedGemma
Google's open-weight medical AI model family for building healthcare a...
Visit
|
Wysa
FDA Breakthrough-designated AI mental health companion delivering CBT...
Visit
|
Airdoc 鹰瞳科技
HK-listed AI retinal screening for eye and chronic-disease risk
Visit
|
Lunit
KOSDAQ-listed Korean AI for breast and lung cancer screening
Visit
|
|
|---|---|---|---|---|
| RECATOOLS Score | 7.5 / 10 | 7.8 / 10 | 6.8 / 10 | 6.7 / 10 |
| Capability | — | |||
| Value for money | — | |||
| Ease of use | — | |||
| ASEAN readiness | — | |||
| API quality | — | |||
| Pricing | Open Source | Freemium | Enterprise | Enterprise |
| Free tier | Open weights downloadable free from Hugging Face; run locally or on your own infrastructure under Google's health AI model terms. | Core AI companion, limited CBT/DBT sessions, mood tracking — no credit card required | — | — |
| Paid from | — | Premium ~USD 29.99/month; Enterprise custom pricing | — | — |
| Has API | ✗ | ✓ | ✗ | ✗ |
| Open source | ✓ | ✗ | ✗ | ✗ |
| Free to use | ✓ | ✓ | ✗ | ✗ |
| Users | — | 6 million+ users; 500 million+ conversations across 95 countries | — | — |
| Founded | 2025 | 2015 | — | — |
| Maker | Touchkin eServices Private Limited | — | — | |
| Verdict | What this is for: A foundation for developers building healthcare AI on medical text and images — classification, retrieval, report drafting and clinical NLP. Who this is for: Healthcare AI developers and researchers, n... |
An FDA Breakthrough Device Designation from May 2022 puts Wysa in rare company among consumer mental-health apps — regulatory validation, not just wellness-app marketing. NHS data backs it up: 31 Talking Therapies servic... |
A single retinal photo, read by Airdoc's model in about three minutes, is enough to flag diabetic retinopathy and eight other chronic-disease risk indicators alongside 35 named eye conditions — a genuinely differentiated... |
Lunit is the most clinically validated medical-AI company to come out of Korea, and one of the few in the category with real revenue rather than just pilot deployments — Q1 2026 revenue hit 24 billion won, up nearly 25%... |
| Full review → | Full review → | Full review → | Full review → |
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.